ArticleInfection and drug resistance2011
Lyme disease: the next decade.
Article in Infection and drug resistance, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Pooled it
- Evidence for the Presence ofMicroorganisms · 2024Article
- Human Babesia odocoilei and Bartonella spp. co-infections in the Americas.Parasites & vectors · 2024Article
- Immunoinformatics-Based Proteome Mining to Develop a Next-Generation Vaccine Design againstVaccines · 2022Article
- Borrelia burgdorferi, the Lyme disease spirochete, possesses genetically-encoded responses to doxycycline, but not to amoxicillin.PloS one · 2022Article
- Lyme Disease in Humans.Current issues in molecular biology · 2021Article
- Antibiotic Treatment Response in Chronic Lyme Disease: Why Do Some Patients Improve While Others Do Not?Healthcare (Basel, Switzerland) · 2020Article
- A Clinical Diagnostic System for Late-Stage Neuropsychiatric Lyme Borreliosis Based upon an Analysis of 100 Patients.Healthcare (Basel, Switzerland) · 2020Article
- Specific composition of polyphenolic compounds with fatty acids as an approach in helping to reduce spirochete burden in Lyme disease:Therapeutic advances in chronic disease · 2020Article
- Classification and Staging of Morgellons Disease: Lessons from Syphilis.Clinical, cosmetic and investigational dermatology · 2020Article
- Motivations and Experiences of Canadians Seeking Treatment for Lyme Disease Outside of the Conventional Canadian Health-Care System.Journal of patient experience · 2018Article
- Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease.Healthcare (Basel, Switzerland) · 2018Article
- The Financial Implications of a Well-Hidden and Ignored Chronic Lyme Disease Pandemic.Healthcare (Basel, Switzerland) · 2018Article
- Relapsing feverInternational journal of general medicine · 2018Article
- Antimicrobial Activity of Bee Venom and Melittin against Borrelia burgdorferi.Antibiotics (Basel, Switzerland) · 2017Article
- Antibody fingerprints in lyme disease deciphered with high density peptide arrays.Engineering in life sciences · 2017Article
- Pleomorphism and Viability of the Lyme Disease PathogenFrontiers in microbiology · 2017Article
- Effect of RpoN, RpoS and LuxS Pathways on the Biofilm Formation and Antibiotic Sensitivity ofEuropean journal of microbiology & immunology · 2016Article
- Lyme disease: the promise of Big Data, companion diagnostics and precision medicine.Infection and drug resistance · 2016Article
- In vitro evaluation of antibacterial activity of phytochemicals and micronutrients against Borrelia burgdorferi and Borrelia garinii.Journal of applied microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Lyme disease remains a controversial illness, recent events have created an unprecedented opportunity to make progress against this serious tick-borne infection. Evidence presented during the legally mandated review of the restrictive Lyme guidelines of the Infectious Diseases Society of America (IDSA) has confirmed the potential for persistent infection with the Lyme spirochete, Borrelia burgdorferi, as well as the complicating role of tick-borne coinfections such as Babesia, Anaplasma, Ehrlichia, and Bartonella species associated with failure of short-course antibiotic therapy. Furthermore, renewed interest in the role of cell wall-deficient (CWD) forms in chronic bacterial infection and progress in understanding the molecular mechanisms of biofilms has focused attention on these processes in chronic Lyme disease. Recognition of the importance of CWD forms and biofilms in persistent B. burgdorferi infection should stimulate pharmaceutical research into new antimicrobial agents that target these mechanisms of chronic infection with the Lyme spirochete. Concurrent clinical implementation of proteomic screening offers a chance to correct significant deficiencies in Lyme testing. Advances in these areas have the potential to revolutionize the diagnosis and treatment of Lyme disease in the coming decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.